{Reference Type}: Journal Article
{Title}: Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population.
{Author}: Jakobsson M;Strambi A;Nilsson F;Arpegård J;Dalén J;
{Journal}: Future Oncol
{Volume}: 20
{Issue}: 20
{Year}: 2024 Jul 26
{Factor}: 3.674
{DOI}: 10.1080/14796694.2024.2351352
{Abstract}: Aim: Assess the time-to-treatment discontinuation (TTD) and overall survival (OS) in a Swedish metastatic renal cell carcinoma (mRCC) nationwide cohort who received second-line axitinib.Methods: Retrospective analysis of 110 patients with mRCC treated with second-line axitinib in Sweden (2012-2019). Patients included in the study received axitinib after mainly first-line sunitinib or pazopanib.Results: The median (95% CI) TTD of patients who received second-line axitinib was 5.2 (3.7-6.1) months with 6 (5.5%) patients still receiving treatment at the time of analysis. Median (95% CI) OS was 12.2 (7.7-14.2) months.Conclusion: The results are consistent with previous findings in mRCC and add to the evidence demonstrating efficacy of second-line axitinib, after failure of a prior anti-angiogenic therapy in a real-world setting.Clinical Trial Registration: NCT04669366 (ClinicalTrials.gov).<BR>[Box: see text].